AstraZeneca PLC (AZN)vsPrestige Brand Holdings Inc (PBH)
AZN
AstraZeneca PLC
$185.95
-0.79%
HEALTHCARE · Cap: $282.69B
PBH
Prestige Brand Holdings Inc
$47.18
+3.83%
HEALTHCARE · Cap: $2.27B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 5451% more annual revenue ($60.44B vs $1.09B). PBH leads profitability with a 17.5% profit margin vs 17.2%. AZN appears more attractively valued with a PEG of 1.39. PBH earns a higher WallStSmart Score of 65/100 (B-).
AZN
Buy64
out of 100
Grade: C+
PBH
Strong Buy65
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Margin of Safety
-54.8%
Fair Value
$42.62
Current Price
$47.18
$4.56 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Reasonable price relative to book value
Attractively priced relative to earnings
Strong operational efficiency at 26.8%
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Weak financial health signals
Revenue declined 5.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : PBH
The strongest argument for PBH centers on Price/Book, P/E Ratio, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 26.8%. PEG of 1.45 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : PBH
The primary concerns for PBH are Piotroski F-Score, Revenue Growth.
Key Dynamics to Monitor
AZN profiles as a mature stock while PBH is a declining play — different risk/reward profiles.
PBH carries more volatility with a beta of 0.35 — expect wider price swings.
AZN is growing revenue faster at 12.5% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
PBH scores higher overall (65/100 vs 64/100), backed by strong 17.5% margins. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Prestige Brand Holdings Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Prestige Consumer Healthcare Inc., develops, manufactures, markets, distributes and sells over-the-counter (OTC) healthcare products in the United States and internationally. The company is headquartered in Tarrytown, New York.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?